Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 25, 2023

Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment for Advanced Acral Melanoma

JAMA Oncology


Additional Info

JAMA Oncology
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial
JAMA Oncol 2023 Jun 01;[EPub Ahead of Print], L Mao, B Lian, C Li, X Bai, L Zhou, C Cui, Z Chi, X Sheng, X Wang, B Tang, X Yan, S Li, Y Kong, J Dai, X Wei, J Li, R Duan, H Xu, X Wu, Y Yang, F Cheng, C Zhang, F Xia, Z Pang, J Guo, L Si

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading